The Vernakalant Story: How Did It Come to Approval in Europe and What is the Delay in the U.S.A?

ISSN: 1875-6557 (Online)
ISSN: 1573-403X (Print)

Volume 13, 4 Issues, 2017

Download PDF Flyer

Current Cardiology Reviews

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Jian'an Wang
School of Medicine Zhejiang University

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

The Vernakalant Story: How Did It Come to Approval in Europe and What is the Delay in the U.S.A?

Current Cardiology Reviews, 10(4): 309-314.

Author(s): A John Camm MD.

Affiliation: Division of Clinical Sciences, St. George's University of London, Cranmer Terrace, London, SW17 0RE, United Kingdom.


The sudden onset of atrial fibrillation (AF) is often associated with rapid irregular palpitations, chest pain, shortness of breath and considerable anxiety. If a patient presents shortly after the onset of the arrhythmia the physician may adopt initially an expectant “wait and see” policy, perhaps with the help of mild sedation and drug therapy to reduce the ventricular rate. If the arrhythmia does not terminate spontaneously and has been present for less than 24-48 hours restoration of sinus rhythm by cardioversion should be considered. This manuscript reviews the option of electrical cardioversion versus pharmacologic and the data for, the role of, and the status of vernakalant with respect to the latter.


Atrial fibrillation, amiodarone, cardioversion, vernakalant.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 10
Issue Number: 4
First Page: 309
Last Page: 314
Page Count: 6
DOI: 10.2174/1573403X10666140513103709
Price: $58
Global Biotechnology Congress 2017Drug Discovery and Therapy World Congress 2017

Related Journals

Related eBooks

Webmaster Contact: Copyright © 2017 Bentham Science